Teladoc Health (NYSE:TDOC) CEO Sells 27,731 Shares

Teladoc Health, Inc. (NYSE:TDOC) CEO Charles Divita III sold 27,731 shares of the company’s stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $5.49, for a total transaction of $152,243.19. Following the completion of the transaction, the chief executive officer directly owned 364,784 shares in the company, valued at $2,002,664.16. This trade represents a 7.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Teladoc Health Stock Down 1.7%

NYSE TDOC traded down $0.10 on Thursday, reaching $5.38. The stock had a trading volume of 3,220,743 shares, compared to its average volume of 6,903,328. The business has a 50 day moving average price of $5.69 and a 200 day moving average price of $7.08. The company has a current ratio of 2.77, a quick ratio of 2.67 and a debt-to-equity ratio of 0.72. Teladoc Health, Inc. has a 1 year low of $4.40 and a 1 year high of $9.77. The company has a market capitalization of $958.88 million, a price-to-earnings ratio of -4.71 and a beta of 2.13.

Teladoc Health (NYSE:TDOC) last posted its quarterly earnings results on Wednesday, February 25th. The health services provider reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.05. The company had revenue of $642.27 million during the quarter, compared to the consensus estimate of $635.33 million. Teladoc Health had a negative return on equity of 9.13% and a negative net margin of 7.92%.The business’s quarterly revenue was up .3% on a year-over-year basis. During the same period last year, the business earned ($0.28) EPS. Teladoc Health has set its Q1 2026 guidance at -0.450–0.350 EPS and its FY 2026 guidance at -1.100–0.700 EPS. On average, analysts forecast that Teladoc Health, Inc. will post -1.16 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. Wells Fargo & Company reduced their target price on shares of Teladoc Health from $8.00 to $6.00 and set an “equal weight” rating for the company in a research note on Thursday, February 26th. Oppenheimer cut their price target on shares of Teladoc Health from $12.00 to $7.00 and set an “outperform” rating on the stock in a report on Tuesday, March 3rd. Barclays assumed coverage on shares of Teladoc Health in a research note on Tuesday, December 9th. They issued an “equal weight” rating and a $8.50 price objective for the company. BMO Capital Markets decreased their price objective on shares of Teladoc Health from $8.00 to $5.00 and set a “market perform” rating for the company in a report on Thursday, February 26th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Teladoc Health in a research report on Monday, December 29th. Six research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $7.76.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. PNC Financial Services Group Inc. lifted its holdings in shares of Teladoc Health by 177.7% during the fourth quarter. PNC Financial Services Group Inc. now owns 4,391 shares of the health services provider’s stock worth $31,000 after buying an additional 2,810 shares during the last quarter. IFP Advisors Inc increased its position in Teladoc Health by 412.1% during the third quarter. IFP Advisors Inc now owns 3,989 shares of the health services provider’s stock worth $31,000 after acquiring an additional 3,210 shares during the period. Aster Capital Management DIFC Ltd raised its stake in Teladoc Health by 101.1% during the 3rd quarter. Aster Capital Management DIFC Ltd now owns 4,823 shares of the health services provider’s stock valued at $37,000 after purchasing an additional 2,425 shares during the last quarter. International Assets Investment Management LLC acquired a new position in Teladoc Health during the 4th quarter valued at $45,000. Finally, Bayforest Capital Ltd bought a new stake in Teladoc Health in the 3rd quarter valued at $58,000. 76.82% of the stock is owned by institutional investors.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.